Imunoterapie u pacientů s karcinomem plic na MOÚ: účinnost, bezpečnost a náklady

Warning

This publication doesn't include Faculty of Economics and Administration. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Title in English Immunotherapy in patients with lung cancer at the Masaryk Memorial Cancer Institute: efficacy, safety and costs
Authors

BÁRTOVÁ Adéla ŘÍHOVÁ Barbora

Year of publication 2023
Type Conference abstract
MU Faculty or unit

Faculty of Medicine

Citation
Description The aim of the analysis was to perform a comprehensive evaluation of the efficacy and cost of checkpoint inhibitors (pembrolizumab, nivolumab, durvalumab, atezolizumab and nivolumab in combination with ipilimumab) in patients with metastatic or locally advanced non-small cell lung cancer (NSCLC) based on real clinical data. The analysis also includes a review of the incidence of immune-mediated adverse events in these patients.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.